Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data s Profits Fall by 59 Percent in Q3; Revenues Essentially Unchanged

NEW YORK, Nov. 15 (GenomeWeb News) - Clinical Data today announced a slight decrease in revenues and a 59-percent decrease in net income for the third quarter.


For the quarter ended Sept. 30, Clinical Data reported revenues of $12.9 million, down a hair from $13 million the same quarter a year ago. Clinical Data's net income decreased to $377,000, or $0.09 per basic share, in Q3, from $910,000, or $0.21 per basic share, in the year-ago period.


The company did not break out R&D expenses or cash on hand.


In October, Clinical Data closed on a $56 million acquisition of Genaissance.


"Our efforts at integrating the operations of Genaissance Pharmaceuticals are progressing well as we refocus Genaissance's service offerings and streamline its operations," Israel Stein, Clinical Data's president, said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.